Literature DB >> 9760294

Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension.

J X Yuan1, A M Aldinger, M Juhaszova, J Wang, J V Conte, S P Gaine, J B Orens, L J Rubin.   

Abstract

BACKGROUND: Primary pulmonary hypertension (PPH) is a rare disease of unknown cause. Although PPH and secondary pulmonary hypertension (SPH) share many clinical and pathological characteristics, their origins may be disparate. In pulmonary artery smooth muscle cells (PASMCs), the activity of voltage-gated K+ (KV) channels governs membrane potential (Em) and regulates cytosolic free Ca2+ concentration ([Ca2+]cyt). A rise in [Ca2+]cyt is a trigger of vasoconstriction and a stimulus of smooth muscle proliferation. METHODS AND
RESULTS: Fluorescence microscopy and patch clamp techniques were used to measure [Ca2+]cyt, Em, and KV currents in PASMCs. Mean pulmonary arterial pressures were comparable (46+/-4 and 53+/-4 mm Hg; P=0.30) in SPH and PPH patients. However, PPH-PASMCs had a higher resting [Ca2+]cyt than cells from patients with SPH and nonpulmonary hypertension disease. Consistently, PPH-PASMCs had a more depolarized Em than SPH-PASMCs. Furthermore, KV currents were significantly diminished in PPH-PASMCs. Because of the dysfunctional KV channels, the response of [Ca2+]cyt to the KV channel blocker 4-aminopyridine was significantly attenuated in PPH-PASMCs, whereas the response to 60 mmol/L K+ was comparable to that in SPH-PASMCs.
CONCLUSIONS: These results indicate that KV channel function in PPH-PASMCs is inhibited compared with SPH-PASMCs. The resulting membrane depolarization and increase in [Ca2+]cyt lead to pulmonary vasoconstriction and PASMC proliferation. Our data suggest that defects in PASMC KV channels in PPH patients may be a unique mechanism involved in initiating and maintaining pulmonary vasoconstriction and appear to play a role in the pathogenesis of PPH.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9760294     DOI: 10.1161/01.cir.98.14.1400

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  97 in total

Review 1.  Primary pulmonary hypertension: the pressure rises for a gene.

Authors:  J R Thomson; R C Trembath
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

Review 2.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  Enhanced Ca(2+)-sensing receptor function in idiopathic pulmonary arterial hypertension.

Authors:  Aya Yamamura; Qiang Guo; Hisao Yamamura; Adriana M Zimnicka; Nicole M Pohl; Kimberly A Smith; Ruby A Fernandez; Amy Zeifman; Ayako Makino; Hui Dong; Jason X-J Yuan
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

Review 4.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

5.  Stromatoxin-sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter.

Authors:  Xi Zoë Zhong; Khaled S Abd-Elrahman; Chiu-Hsiang Liao; Ahmed F El-Yazbi; Emma J Walsh; Michael P Walsh; William C Cole
Journal:  J Physiol       Date:  2010-09-27       Impact factor: 5.182

Review 6.  An overview of potential molecular mechanisms involved in VSMC phenotypic modulation.

Authors:  Ming-Jie Zhang; Yi Zhou; Lei Chen; Yan-Qin Wang; Xu Wang; Yan Pi; Chang-Yue Gao; Jing-Cheng Li; Li-Li Zhang
Journal:  Histochem Cell Biol       Date:  2015-12-26       Impact factor: 4.304

Review 7.  Pulmonary Hypertension and ATP-Sensitive Potassium Channels.

Authors:  Conor McClenaghan; Kel Vin Woo; Colin G Nichols
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

8.  Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway.

Authors:  Christopher C Sullivan; Lingling Du; Danny Chu; Augustine J Cho; Masakuni Kido; Paul L Wolf; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 10.  High altitude pulmonary hypertension: role of K+ and Ca2+ channels.

Authors:  Carmelle V Remillard; Jason X-J Yuan
Journal:  High Alt Med Biol       Date:  2005       Impact factor: 1.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.